JADA Foundation President Jimmie Wilson pens Op-Ed for Washington Post
How risky can the weight-loss drug bomm be? I learned the hard way.
Unregulated copycat versions of GLP-1 are a dangerous blind spot.
The JADA Foundation Requests Kentucky Attorney General Review of Compounded GLP-1 / GIP Drug Practices
The JADA Foundation, Inc., a Kentucky-based 501(c)(3) public charity, has formally submitted a request to the Office of the Attorney General of Kentucky seeking an independent review of consumer-facing practices related to compounded GLP-1 and GIP drug products available to Kentucky residents.
The referral was submitted on February 20, 2026, and this public announcement is being made subsequently to allow for the appropriate advancement of the evaluation process and to respect the independence of any review undertaken.
The request asks the Attorney General’s Office to evaluate, within its discretion, areas such as:
- Marketing and advertising representations to consumers
- Transparency regarding FDA approval status and compounding practices
- Telehealth prescribing models and consumer protections
- Labeling, sourcing, and formulation concerns
- Broader consumer protection considerations under Kentucky law
“Patients reasonably believe that safeguards are in place to protect them. But when safety expectations exist as guidance rather than enforceable standards, the system is not actively ensuring outcomes—it is relying on them. When that happens, the consequences are not absorbed by the system, but by patients and families.”
— Carl D. Wilson, Chair, The JADA Foundation, Inc
MUST READ!
JADA ALERTS -
Eli Lilly - Open Letter
Lilly flags safety risk in compounded Zepbound mixed with vitamin B12
Eli Lilly & Co. warned that the active ingredient in its weight-loss blockbuster Zepbound could pose a risk to patients when mixed with vitamin B12, a combination sold by US drug compounders.
Lilly tested compounded products and found “significant levels of an impurity” resulting from a chemical reaction between the vitamin and the active ingredient, tirzepatide, it said Thursday.
Bloomberg
Marthe Fourcade
Reporter
March 12, 2026
JADA Alerts - Novo Hit with FDA Warning Letter for Unreported Ozempic Safety Signals
Novo Nordisk received a warning letter last week from the FDA for failing to investigate and report adverse events potentially linked to its blockbuster GLP-1 drug Ozempic—including deaths.
“You failed to promptly investigate reports of serious and unexpected events as 15-Day Alert reports instead of periodic individual case reports (ICSRs),” an FDA inspector wrote in a report, adding that Novo did not abide by its own protocol to follow up twice with the reporters of the side effects. Among the safety events that went uninvestigated, according to the regulator, are two deaths—one dated Jan. 30, 2024, and another Dec. 20, 2024—and one suicide. All three were linked to Ozempic.
March 12,
2026
Tristan Manalac
Newsbreak
JADA Alerts -
FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s
March 2026
FDA News Release
March 3, 2026
The U.S. Food and Drug Administration today announced the issuance of 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products offered on their websites.
JADA Alerts -
FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs
March 2026
Martin A Makary, M.D., M.P.H.
Commissioner of Food and Drugs - Food and Drug Administration
February 06, 2026
U.S. Food and Drug Administration is announcing its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies — including Hims & Hers and other compounding pharmacies — as similar alternatives to FDA-approved drugs. These actions are aimed to safeguard consumers from drugs for which the FDA cannot verify quality, safety, or efficacy. We take seriously any potential violations of the Federal Food, Drug, and Cosmetic Act.
JADA Alerts - GLP/Compounding News
February
2026
Chris Ingalls
Investigative Reporter
KING 5 TV, Seattle.
Send your tip: cingalls@king5.com
Kirkland startup pharmacy hires unlicensed workers to handle GLP-1 medications, whistleblowers say
Whistleblowers expose unlicensed workers handling prescription medications at Kirkland pharmacy that supplied GLP-1 weight-loss drugs nationwide.
If you or anyone you know has had problems with Mochi and its delivery of weight-loss medications, contact the KING 5 Investigators at investigators@king.com.
JADA Alerts - GLP/Compounding News
Washington Poison Center calls related to GLP-1 diet drugs double since 2024
Popular medications like Ozempic and Wegovy transform American waistlines, but a KING 5 investigation finds a troubling surge in overdoses and emergency calls.
February
2026
Chris Ingalls
Investigative Reporter
KING 5 TV, Seattle.
Send your tip: cingalls@king5.com
JADA Alerts - GLP/Compounding News
February 2026
Author(s) Nicholas Jacobus,
David Graziano
PharmExee.com
FDA Enforcement on Copycat GLP-1's Could Reshape Retail Pharmacy Economics: Q&A with David Graziano
David Graziano, head of retail network at GoodRx, says the FDA’s crackdown on non-approved or “copycat” GLP-1 drugs could shift demand toward FDA-approved therapies while increasing the importance of affordable access through retail pharmacies
February
2026
Karl Hille
Investigative Reporter
Baltimore Sun.
FDA cracks down on weight-loss drug alternatives as thousands sickened in Maryland
Popular weight-loss drugs, including Ozempic, Wegovy, Trulicity and Mounjaro, produced by independent pharmacy labs, sickened some 8,000 or more Marylanders a year by 2024
February 2026
Casey Smith
Reporter
Indiana CAPITAL CHRONICLE
Lawmakers finalize Indiana oversight plan for compounded drugs, medical spas
A compromise on compounded drugs and medical spas cleared the Indiana Senate on Thursday, sending the measure to the governor.
February 2026
GLP-1 News Now with Maria
Colorado SB26-066: A State-Level Crackdown on Compounded Weight-Loss Medications
Colorado just introduced a bill that squarely targets one category of compounding: weight-loss medications, especially those built from GLP-1–type ingredients.